Featured Research

from universities, journals, and other organizations

Cell receptor could allow measles virus to target tumors

Date:
August 25, 2011
Source:
Public Library of Science
Summary:
Canadian researchers have discovered that a tumor cell marker is a receptor for measles virus, suggesting the possible use of measles virus to help fight cancer.

Canadian researchers have discovered that a tumor cell marker is a receptor for measles virus, suggesting the possible use of measles virus to help fight cancer.

Their findings appear in the Open Access journal PLoS Pathogens.

Viruses cause infection by attaching to specific proteins on cell surfaces called receptors. Dr. Chris Richardson of Dalhousie Medical School in Halifax, Nova Scotia, Canada and colleagues found that the tumor cell marker, PVRL4 (Nectin 4), is a receptor for measles virus.

The PVRL4 receptor is found in airway cells, and measles virus infects tissue in the respiratory tract and lungs. Large amounts of PVRL4 are also present in many cancers that originate from cells of the lung, breast, colon, and ovaries.

The receptor was discovered by comparing the proteins made in virus-susceptible cancer cells to those present in cells resistant to the virus. Because PVRL4 is found in many types of human cancers, the measles virus could potentially be used to specifically infect cancer cells and turn the immune system against tumors.

The cancer killing properties of measles virus have previously been reported by researchers at the Mayo Clinic, but this is the first time that the virus has been shown to target a common receptor that is highly expressed on the surfaces of lung, breast, colon, and ovarian cancer cells. The approach could be used to fight many different types of cancer.

Ongoing experiments are being performed to test the approach in mouse tumor models.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ryan S. Noyce, Daniel G. Bondre, Michael N. Ha, Liang-Tzung Lin, Gary Sisson, Ming-Sound Tsao, Christopher D. Richardson. Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus. PLoS Pathogens, 2011; 7 (8): e1002240 DOI: 10.1371/journal.ppat.1002240

Cite This Page:

Public Library of Science. "Cell receptor could allow measles virus to target tumors." ScienceDaily. ScienceDaily, 25 August 2011. <www.sciencedaily.com/releases/2011/08/110825172459.htm>.
Public Library of Science. (2011, August 25). Cell receptor could allow measles virus to target tumors. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/08/110825172459.htm
Public Library of Science. "Cell receptor could allow measles virus to target tumors." ScienceDaily. www.sciencedaily.com/releases/2011/08/110825172459.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins